A prospective phase III validation study found that AZGP1 has significant prognostic utility as a biomarker in localized prostate cancer.
Experimental, minimally invasive “liquid biopsy” blood tests might soon help to personalize prostate cancer treatment by predicting androgen resistance and survival benefits from particular treatments.
The FDA has granted accelerated approval to atezolizumab (Tecentriq) for the treatment of locally advanced or metastatic urothelial carcinoma—the most common type of bladder cancer.
The anti-PD-L1 antibody atezolizumab showed significantly improved objective response rates compared to historic controls in a phase II study of patients with locally advanced or metastatic urothelial carcinoma previously treated with platinum-based therapy.
Comprehensive genomic profiling of patients with advanced urothelial carcinoma has revealed a very high frequency of clinically relevant genomic alterations.
A phase II trial found that use of a personalized peptide vaccination improved overall survival in patients with chemotherapy-resistant advanced urothelial bladder cancer.
Researchers have developed a blood test that can identify mutations in the androgen receptor gene that drive resistance to abiraterone. The test could identify prostate cancer patients who will not respond to the treatment.
Phase II study results found that half of patients with relapsed or refractory urothelial carcinoma responded to treatment with pazopanib and paclitaxel.
A full-term infant presents with abdominal distention and enlarged kidneys. After further evaluation, a biopsy is performed. What is your diagnosis?
An external validation study has confirmed that biomarkers of the mTOR pathway have prognostic value in patients with clear cell renal cell carcinoma.